Obesity and Insulin Resistance, Not Polycystic Ovary Syndrome, Are Independent Predictors of Bone Mineral Density in Adolescents and Young Women.
Adolescents
Body mass index
Bone mineral density
Polycystic ovary syndrome
Journal
Hormone research in paediatrics
ISSN: 1663-2826
Titre abrégé: Horm Res Paediatr
Pays: Switzerland
ID NLM: 101525157
Informations de publication
Date de publication:
2019
2019
Historique:
received:
26
09
2019
accepted:
09
03
2020
pubmed:
30
4
2020
medline:
11
7
2020
entrez:
30
4
2020
Statut:
ppublish
Résumé
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders that affects females of reproductive age. The characteristic features of PCOS individually have opposing effects on bone mineral density (BMD); however, their cumulative effect on BMD has not been clearly defined. Adolescence and young adulthood span a crucial period in achieving peak bone mass. Thus, a better understanding of the impact of PCOS on BMD in this age group is needed. To determine whether BMD is different between young females with PCOS and controls and to identify factors that influence BMD in this population. Data from four cross-sectional studies with a total of 170 females aged 12-25 years with PCOS (n = 123) and controls (n = 47) with a wide range of BMIs (18.7-53.4 kg/m2) were analyzed. Participants had fasting glucose, insulin, and free and total testosterone concentrations measured. HOMA-IR was calculated. Whole-body BMD was assessed by dual-energy X-ray absorptiometry. Multiple regression analysis for predicting BMD included PCOS status, menstrual age, obesity, HOMA-IR, and free testosterone. HOMA-IR and total and free testosterone were significantly higher in PCOS compared to controls but there was no difference in BMD z-score between PCOS (0.8 ± 1.0) and controls (0.6 ± 1.0) (p = 0.36). Obesity (p = 0.03) and HOMA-IR (p = 0.02) were associated with BMD z-score. Obesity status and insulin resistance, but not PCOS status, were each independently associated with BMD in adolescents and young women who spanned a wide range of BMIs.
Identifiants
pubmed: 32348991
pii: 000507079
doi: 10.1159/000507079
pmc: PMC7308184
mid: NIHMS1580793
doi:
Substances chimiques
Testosterone
3XMK78S47O
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-371Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK107871
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR000081
Pays : United States
Informations de copyright
© 2020 S. Karger AG, Basel.
Références
Front Endocrinol (Lausanne). 2016 Mar 07;6:190
pubmed: 27014187
Int J Clin Pract. 2010 May;64(6):817-20
pubmed: 20518955
J Bone Miner Res. 2014 Jan;29(1):223-33
pubmed: 23775829
J Pediatr Adolesc Gynecol. 2012 Aug;25(4):248-53
pubmed: 22840935
Hum Reprod. 2001 Jun;16(6):1255-60
pubmed: 11387301
Clin Endocrinol (Oxf). 2005 Jun;62(6):683-91
pubmed: 15943830
Osteoporos Int. 2005 Nov;16(11):1330-8
pubmed: 15928804
Fertil Steril. 2016 Jul;106(1):6-15
pubmed: 27233760
Arch Biochem Biophys. 2010 Nov 1;503(1):20-7
pubmed: 20599663
Eur J Obstet Gynecol Reprod Biol. 2004 Aug 10;115(2):200-5
pubmed: 15262356
Obstet Gynecol. 2001 Sep;98(3):445-9
pubmed: 11530127
Osteoporos Int. 1998;8(5):436-42
pubmed: 9850351
Fertil Steril. 2018 Aug;110(3):364-379
pubmed: 30033227
Lancet. 2007 Aug 25;370(9588):685-97
pubmed: 17720020
J Endocrinol. 2017 Feb;232(2):R99-R113
pubmed: 27895088
Trends Endocrinol Metab. 2012 Nov;23(11):576-81
pubmed: 22595550
J Bone Miner Metab. 2001;19(4):257-62
pubmed: 11448019
Fertil Steril. 1999 Jul;72(1):21-5
pubmed: 10428143
Metabolism. 1996 Apr;45(4):515-8
pubmed: 8609841
Clin Endocrinol (Oxf). 1998 Feb;48(2):169-73
pubmed: 9579228
Obesity (Silver Spring). 2016 Nov;24(11):2399-2406
pubmed: 27804265
Fertil Steril. 2013 Aug;100(2):470-7
pubmed: 23756098
J Adolesc Health. 2010 Dec;47(6):591-5
pubmed: 21094436
J Bone Miner Metab. 2009;27(5):629-33
pubmed: 19373519
J Endocr Soc. 2019 Jun 14;3(8):1545-1573
pubmed: 31384717
Physiol Rev. 2001 Jan;81(1):419-447
pubmed: 11152762
J Bone Miner Res. 2012 Feb;27(2):294-300
pubmed: 22095911
J Clin Endocrinol Metab. 2016 Aug;101(8):3114-22
pubmed: 27243136
J Clin Endocrinol Metab. 1997 Sep;82(9):2821-5
pubmed: 9284703
Endocrine. 2012 Dec;42(3):546-54
pubmed: 22547367
J Bone Miner Res. 2012 Jan;27(1):119-24
pubmed: 21915902
J Endocrinol Invest. 2014 Dec;37(12):1219-24
pubmed: 25245338
J Bone Miner Res. 1998 Nov;13(11):1739-46
pubmed: 9797483
Osteoporos Int. 2001;12(8):630-8
pubmed: 11580076
Diabet Med. 2000 Feb;17(2):124-9
pubmed: 10746482
J Endocr Soc. 2017 Jun 01;1(7):931-944
pubmed: 29264544
Int J Environ Res Public Health. 2016 May 28;13(6):
pubmed: 27240395
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3303-3310
pubmed: 30802282
J Clin Endocrinol Metab. 2013 Jun;98(6):2562-72
pubmed: 23515452
N Engl J Med. 1995 Mar 23;332(12):767-73
pubmed: 7862179
J Pediatr. 2017 Jan;180:261-269
pubmed: 27816219
Expert Rev Endocrinol Metab. 2013 Sep;8(5):449-459
pubmed: 30754191
Nat Rev Endocrinol. 2013 Dec;9(12):699-712
pubmed: 24042328
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
J Clin Endocrinol Metab. 1997 Oct;82(10):3493-7
pubmed: 9329391
Osteoporos Int. 1994;4 Suppl 1:7-13
pubmed: 8081064
Fertil Steril. 2005 May;83(5):1454-60
pubmed: 15866584